ERBB2 and breast carcinoma: Patients with HER2-positive breast cancer are given HER2-targeted therapies in combination with a chemotherapy backbone, select patients with TNBC are treated with immunotherapy in combination with chemotherapy, high-risk HR+/HER2-negative patients receive endocrine therapy with cyclin-dependent kinase (CDK) inhibitors, and high-risk patients with pathogenic breast cancer (BRCA) gene mutations benefit from the use of adjuvant PAPR inhibitors [3].